Thiol-Ene Hydrogel Strings for Biocompatible Cell Encapsulation

The patent combines alginate with thiol-ene crosslinked polymers to create a composite hydrogel material. The alginate provides ease of manufacture and basic gelation properties, while the thiol-ene polymer network adds structural integrity, biocompatibility, and controlled degradation properties that enable in vivo therapeutic success. This composite approach allows the material to simultaneously achieve manufacturability and therapeutic reliability.

The patent modifies the chemical parameters of synthetic polymers by introducing thiol-ene crosslinking chemistry with specific functional groups (vinyl sulfone, maleimide, acrylate) that control the mechanical properties and degradation rate. By adjusting crosslinking density, molecular weight, and functional group composition, the material achieves optimal structural integrity while maintaining biocompatibility and minimizing immune response through controlled elution of degradation products.

The patent divides the crosslinking process into distinct functional segments: alginate provides ionic crosslinking for basic structure, while thiol-ene chemistry provides covalent crosslinking for enhanced integrity. This segmentation allows each chemical system to be optimized independently and simplifies manufacturing by enabling sequential or simultaneous gelation without requiring complex multi-step processes.

The patent creates local quality variations within the hydrogel structure by controlling crosslinking density gradients and incorporating porogenic agents. The alginate-thiol-ene composite structure provides regions of high structural integrity (thiol-ene crosslinked networks) while maintaining regions of higher porosity and water content (alginate hydrophilic domains) that facilitate nutrient and waste diffusion. This local differentiation allows simultaneous optimization of mechanical strength and mass transport.